The present invention relates to a new use of NMR for quantitatively ranking transient ligand binding to target biomolecules.
The molecular nature of protein-ligand associations is a subject of tremendous interest in chemistry, biochemistry and pharmaceutical drug discovery research (Kuntz, I. D., Chen, K., Sharp, K. A., and Kollman, P. A. (1999) Proc.Natl.Acad.Sci.U.S.A 96, 9997-10002; and Brooijmans, N., Sharp, K. A., and Kuntz, I. D. (2002) Proteins 48, 645-653). Targeting enzymes and protein surfaces involved in molecular regulatory pathways by low-molecular-weight molecules leads to various means of maintaining human health and treating diseases. Thermodynamic analyses of complex formation, such as equilibrium binding experiments and enzyme inhibition assays, have provided valuable information regarding the molecular/atomic forces that dictate the structural stability of protein-ligand complexes (Kuntz, I. D., Chen, K., Sharp, K. A., and Kollman, P. A. (1999) Proc.Natl.Acad.Sci.U.S.A 96, 9997-10002; and Brooijmans, N., Sharp, K. A., and Kuntz, I. D. (2002) Proteins 48, 645-653). In general, however, it is still difficult if not impossible to explain quantitatively the exact correlations between molecular structures and the binding affinity of protein-ligand complexes (Kuntz, I. D., Chen, K., Sharp, K. A., and Kollman, P. A. (1999) Proc.Natl.Acad.Sci.U.S.A 96, 9997-10002). In most cases, the difficulties are related to the failure to account for even subtle molecular motions in the otherwise very exact dimensions of microscopic protein-ligand interactions captured by high-resolution molecular structures (Kuntz, I. D., Chen, K., Sharp, K. A., and Kollman, P. A. (1999) Proc.Natl.Acad.Sci.U.S.A 96, 9997-10002; and Nienaber, V. L., Mersinger, L. J., and Kettner, C. A. (1996) Biochemistry 35, 9690-9699; and Carlson, H. A. (2002) Curr.Opin.Chem.Biol. 6, 447-452). On top of all these, there is as yet no clear understanding of the relationship between binding, kinetics and molecular structure of protein-ligand interactions (Van Regenmortel, M. H. (2001) Cell Mol.Life Sci. 58, 794-800; and Andersson, K., Choulier, L., Hamalainen, M. D., Van Regenmortel, M. H., Altschuh, D., and Malmqvist, M. (2001) J.Mol.Recognit. 14, 62-71; and Day, Y. S., Baird, C. L., Rich, R. L., and Myszka, D. G. (2002) Protein Sci. 11, 1017-1025). The significance of protein-ligand binding kinetics becomes particularly high in vivo, where transient complexes are formed and broken as a cause or in response to biomolecular regulatory mechanisms.
A number of techniques are already available for quantitating the kinetics of protein-protein and protein-ligand interactions, such as surface plasmon resonance (Van Regenmortel, M. H. (2001) Cell Mol.Life Sci. 58, 794-800; and Wilson, W. D. (2002) Science 295, 2103-2105) and analysis of the progress curves of enzyme inhibition by specific ligands (Pargellis, C. A., Morelock, M. M., Graham, E. T., Kinkade, P., Pav, S., Lubbe, K., Lamarre, D., and Anderson, P. C. (1994) Biochemistry 33, 12527-12534; and Day, Y. S., Baird, C. L., Rich,. R. L., and Myszka, D. G. (2002) Protein Sci. 11, 1017-1025). All these methodologies are limited to the characterization of tight-binding or slow-dissociating protein-ligand complexes with lifetimes longer than at least several seconds (Van Regenmortel, M. H. (2001) Cell Mol.Life Sci. 58, 794-800; and Day, Y. S., Baird, C. L., Rich, R. L., and Myszka, D. G. (2002) Protein Sci. 11, 1017-1025). Another limitation of these methods is that they only provide a macroscopic description of binding kinetics, without details of the dynamic behavior of the interacting molecules at atomic resolution.
Short-lived or transient, but specific-binding, protein-ligand complexes represent a good starting point for the design of high affinity inhibitors or effectors (Wells, J. A. (1996) Science 273, 449450; and Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S. W. (1996) Science 274, 1531-1534). These fast dissociating ligands are often derived from naturally occurring protein-protein interfaces (Song, J. and Ni, F. (1998) Biochem.Cell Biol. 76, 177-188) or discovered by screening against peptide and/or protein libraries (Wells, J. A. (1996) Science 273, 449450; and Mourez, M., Kane, R. S., Mogridge, J., Metallo, S., Deschatelets, P., Sellman, B. R., Whitesides, G. M., and Collier, R. J. (2001) Nat.Biotechnol. 19, 958-961). Even without affinity “maturation”, these specific-binding ligands can be converted into bivalent and polyvalent molecules with a dramatic increase in affinity and decrease in the dissociation rates (Song, J. and Ni, F. (1998) Biochem.Cell Biol. 76, 177-188; and Mammen, M., Choi, S.-K., and Whitesides, G. M. (1998) Angew.Chem.Int.Ed. 37, 2754-2794; and Rao, J., Lahiri, J., Isaacs, L., Weis, R. M., and Whitesides, G. M. (1998) Science 280, 708-711; and Kramer, R. H. and Karpen, J. W. (1998) Nature 395, 710-713; and Kitov, P. I., Sadowska, J. M., Mulvey, G., Armstrong, G. D., Ling, H., Pannu, N. S., Read, R. J., and Bundle, D. R. (2000) Nature 403, 669-672; and Fan, E., Zhang, Z., Minke, W. E., Hou, Z., Verlinde, C. L. M. J., and Hol, W. G. J. (2000) J.Am.Chem.Soc. 122, 2663-2664; and Kiessling, L. L., Gestwicki, J. E., and Strong, L. E. (2000) Curr.Opin.Chem.Biol. 4, 696-703; and Mourez, M., Kane, R. S., Mogridge, J., Metallo, S., Deschatelets, P., Sellman, B. R., Whitesides, G. M., and Collier, R. J. (2001) Nat.Biotechnol. 19, 958-961).
Nuclear magnetic resonance (NMR) spectroscopy has been established as one of the most powerful tools for studying the kinetic processes in chemical systems. Fast chemical interconversions often lead to extensive broadening of the NMR signals, from which the underlining rate constants and energetic parameters can be derived (Sandstrom, J. (1982) Dynamic NMR spectroscopy. London: Academic Press; and Blackledge, M. J., Bruschweiler, R., Griesinger, C., Schmidt, J. M., Xu, P., and Ernst, R. R. (1993) Biochemistry 32, 10960-10974). In contrast, fast exchange processes in biological systems have very rarely been measured in the details needed for an adequate understanding of the underlying kinetic processes. The binding kinetics of large and transient enzyme-inhibitor and protein-ligand complexes were only estimated by use of NMR spectroscopy and other methods (Jardetzky, O. and Roberts, G. C. K. (1981) NMR in molecular biology. New York: Academic Press; and Hammes, G. G. (1982) Enzyme catalysis and regulation. New York: Academic Press). Some earlier attempts at quantitative measurements utilized mostly 19F NMR, including spin-lock T1p), T1/T2 and T2 (CPMG) relaxation experiments (Sykes, B. D. (1969) J.Am.Chem.Soc. 91, 949-955; and Smallcombe, S. H., Ault, B., and Richards, J. H. (1972).J.Am.Chem.Soc. 94, 4585-4590; and Gerig, J. T. and Stock, A. D. (1975) Org.Magn.Res. 7, 249-255; and Gerig, J. T., Halley, B. A., and Ortiz, C. E. (1977) J.Am.Chem.Soc. 99, 6219-6226; and Dubois, B. W. and Evers, A. S. (1992) Biochemistry 31, 7069-7076) and spectral lineshape analysis (Jacobson, A. R. and Gerig, J. T. (1991) J.Biomol.NMR 1, 131-144). More recent developments include combined analyses of proton T1, T1p, T2 and T2 (CPMG) relaxation data (Davis, D. G., Perlman, M. E., and London, R. E. (1994) J.Magn Reson.B 104, 266-275) or the use of 19F cross-correlated relaxation measurements (Peng, J. W. (2001) J.Magn Reson. 153, 32-47) to help deconvolute the relaxation dispersion curves of the ligand molecules. The NMR T2 (CPMG) relaxation measurements in particular appeared to be a promising technique for quantitating the binding kinetics of rapidly-dissociating protein-ligand complexes (Carver, J. P. and Richards, R. E. (1972) J.Magn.Reson. 6, 89-105; and Gerig, J. T. and Stock, A. D. (1975) Org.Magn.Res. 7, 249-255; and Gerig, J. T., Halley, B. A., and Ortiz, C. E. (1977) J.Am.Chem.Soc. 99, 6219-6226; and Dubois, B. W. and Evers, A. S. (1992) Biochemistry 31, 7069-7076; and Davis, D. G., Perlman, M. E., and London, R. E. (1994) J.Magn Reson.B 104, 266-275).
The kinetics of transient protein-ligand interactions has been investigated recently in a few cases, one for a small protein-peptide complex (Hensmann, M., Booker, G. W., Panayotou, G., Boyd, J., Linacre, J., Waterfield, M., and Campbell, I. D. (1994) Protein Sci. 3, 1020-1030; and Gunther, U., Mittag, T., Schaffhausen, and B. (2002) Biochemistry 41, 11658-11669), and some for enzyme-substrate/inhibitor interactions (Deng, H., Zhadin, N., and Callender, R. (2001) Biochemistry 40, 3767-3773; and Gulotta, M., Deng, H., Deng, H., Dyer, R. B., and Callender, R. H. (2002) Biochemistry 41, 3353-3363; and Hammes, G. G. (2002) Biochemistry 41, 8221-8228). The studied protein-peptide complex in particular involves binding of a small protein (MW˜12 kDa) with a phosphotyrosine-containing peptide with equilibrium dissociation constant in the 30-100 nM range (Hensmann, M., Booker, G. W., Panayotou, G., Boyd, J., Linacre, J., Waterfield, M., and Campbell, I. D. (1994) Protein Sci. 3, 1020-1030). To characterize binding kinetics of the protein-peptide complex, the protein was recombinantly expressed, enriched uniformly with the 15N isotope, and the NMR peak shapes in response to peptide titrations were analyzed. As a practical alternative, it is particularly attractive to deconvolute the kinetic contributions to protein-ligand interactions by following the NMR spectroscopic and relaxation behaviors of the small ligand molecules. This approach expands the capability of quantitating dissociation kinetics to systems where the binding proteins and other biomolecules are large or not perfectly folded, and therefore are not normally or easily accessible to direct NMR observation. In addition, the target proteins do not have to be isotopically labeled and therefore can be purified from the natural sources or from a wide range of recombinant expression systems. Small ligand molecules require considerably less amount of time for NMR signal identification, and can be observed and resolved spectroscopically when mixed with other molecules with comparable molecular weights. The challenge here lies in the difficulty or impossibility to observe the bound states of the ligands due to the high molecular weight of the protein-ligand complex, such that conclusions may depend on the kinetic mechanism chosen to explain the experimental data.
One aim of the present invention is to provide a new use of the dissociation rates (koff) of protein-ligand complexes as a measure of the potency of ligand molecules binding transiently to target proteins and other biomolecules.
Another aim of the present invention is to provide an efficient method for quantitating the fast dissociation rates of transient protein-ligand complexes with lifetimes ranging from a few milliseconds to hundreds of microseconds.
In accordance with the present invention there is provided an efficient method to quantitate fast dissociation rates of ligands containing one or more, and preferably at least two, magnetic nuclei by performing NMR relaxation dispersion experiments at different protein concentrations, enabling the evaluation of populations and exchange rates, and extending the practical applicability of the NMR relaxation dispersion experiments.
Nuclear magnetic resonance (NMR)-based tools have been developed for quantitating the binding kinetics of transient protein-ligand complexes. More specifically, it is shown herein that implementation of NMR relaxation dispersion spectroscopy in accordance with the present invention can be used to determine the dissociation rate constants or binding off-rates of protein-peptide complexes in the absence of an accurate knowledge of the concentrations of either the peptide or the binding protein.
It was found and detailed herein that the problem of discriminating two-state from multistate binding processes can be resolved by performing NMR relaxation dispersion experiments of only ligand NMR signals at a number of concentrations of the binding protein.
In accordance with the present invention, there is therefore provided a method to identify two or more ligand molecules that can be linked together to create high-affinity molecules. Specifically, it is proposed herein that bivalent or polyvalent molecules with enhanced binding capacity can be constructed from ligand molecules that bind non-competitively or cooperatively. Non-competitivity or positive coooperativity is to be measured by an unchanged or a decreased dissociation rate constant, koff, of one ligand in the presence of other ligand molecules.
In accordance with the present invention, there is therefore provided a method to identify binding hotspots of high-affinity ligand-target interactions through chemical fragmentation of the ligand molecule.
In accordance with the present invention, there is provided a method to identify a ligand site obeying a two-state or more complex binding behavior in a transient complex of a ligand with a target molecule, said method comprising the steps of:
In accordance with the present invention there is provided a method to determine quantitatively the dissociation rate constant (koff) for a transient complex of a ligand with the target molecule comprising the steps of:
The ligand may be for example, without limitation a peptide, a 15N-enriched polypeptide, or a molecule binding to the target under study. The ligand may also be a mixture of any of the above
The target may be for example, without limitation a protein or a protein assembly.
In accordance with the present invention, there is provided the use of the method as defined above to determine amino acid residues with detectable NMR relaxation dispersion as a constituting binding hot-spot.
The method of the present invention may also be used to identify two or more ligands that can be linked together to create high-affinity molecules.
The method of the present invention may still be used to study high-affinity protein-protein interactions or slow-dissociating ligand-target complexes.
It is also proposed that structure-affinity relationships of protein-ligand complexes can be built using the dissociation rate constants alone instead of the commonly used binding equilibrium constants.
a to 9D illustrate 15N relaxation dispersion data at 500 MHz (⋄; 15N frequency: 50.684 MHz) and 800 MHz (□; 15N frequency: 81.076 MHz), and fitted profiles for selected amide nitrogen atoms of the 15N-labeled peptide, N-acetyl-Hir(55-65), in complex with human α-thrombin in 50 mM NaCl and 50 mM sodium phosphate at pH 5.5, and in the presence of 10% D2O;
b and 20C illustrate the [1H—15N]—HSQC spectrum of the 15N-labeled recombinant propeptide with the wild-type amino acid sequence (
The following analysis of 15N NMR relaxation dispersion reveals that it is possible to determine the dissociation rate constant koff of protein-ligand complexes from the NMR relaxation dispersion curves obtained with two or more external magnetic fields and at one or more protein concentrations. More importantly, it is found that the accuracy of the ligand or protein concentrations is not critical for the data analysis, as only the increases in the protein/ligand ratio, measured by the volumes of the titrated protein solution, need to be included in the data fitting process. In particular, it can be shown that if [Lfree]>>KD and [L0]>>[E0],
kon′(second)=[(Vstock1+Vstock2)/Vstock1]×kon′(first)
where Vstock1 is the volume of the protein stock solution used in the first addition, Vstock2 is the volume of the protein stock solution used in the second addition, etc. Any other method of titration allowing determination of the proportionality between the kon′ values at different protein concentrations is also valid.
Simultaneous fitting of the dispersion curves obtained at multiple protein concentrations makes it possible to identify ligand moieties involving more complex exchange mechanisms (including one free and two or more bound states). The nuclei (or ligand moieties) following a two-state binding-dissociation mechanism behave similarly to each other and display reasonable physical parameters, such as koff, pb (apparent fraction of the bound peptide), R2b(500), R2b(800)(apparent R2 relaxation rate of the peptide 15N nuclei in the bound stateat either 500 or 800 MHz), and δωbf (frequency separation of a peptide 15N signal in the free and bound states: δωb-δωf), allowing a more accurate determination of the dissociation rate constants through combined data fitting.
The data analysis procedure can be easily automated, including input of the relaxation dispersion data, model fitting, identification of the sites with two-state binding behavior and calculation of the koff values at multiple protein titrations. In practical implementations it should be kept in mind that the CPMG NMR relaxation dispersion experiments, including 15N relaxation as illustrated here as well as NMR relaxation of other nuclei, such as 1H, 19F, 13C, 31P, etc., have a limited sensitivity to the time scales of the ligand dissociating process, i.e. from tens of milliseconds to hundreds of microseconds. As well, quantitative analysis using the proposed titration procedure without precise knowledge of the ligand and protein concentrations requires the large excess of the ligand over the binding protein and that the ligand concentration be much larger than the dissociation constant of the protein complex (see Eqn 3). In some cases, faster ligand off-rates may be quantitated by the NMR T1p experiments (Mulder, F. A., van Tilborg, P. J., Kaptein, R., and Boelens, R. (1999) J.Biomol.NMR 13, 275-288; and Trott, O. and Palmer, A. G., Ill (2002) J.Magn Reson. 154, 157-160) and multiple quantum relaxations (Wang, C. and Palmer, A. G. (2002) J.Biomol.NMR 24, 263-268).
The new NMR techniques according to the present invention have now also been applied to a mixture of peptides either binding to distinct sites or competing for one site on a target protein (
Materials and Methods
Protein Preparation
Stock solutions of human prothrombin and thrombin were prepared as described previously (Carlisle, T. L., Bock, P. E., and Jackson, C. M. (1990) J.Biol.Chem. 265, 22044-22055; and Fenton, J. W., Fasco, M. J., and Stackrow, A. B. (1977) J.Biol.Chem. 252, 3587-3598; and Ni, F., Ning, Q., Jackson, C. M., and Fenton, J. W. (1993) J.Biol.Chem. 268, 16899-16902). Immediately before use, human thrombin was thawed on ice and concentrated to ˜8 mg/ml using Centricon-10 concentrator (Amicon).
Recombinant Cdc42 (residues 1-178) from Candida Albicans (CaCdc42) was expressed as a His6-tag protein in Escherichia coli BL21 (DE3) (Novagen) using a pET15b-CaCdc42 expression plasmid engineered with a thrombin cleavage site. Uniform enrichment of CaCdc42 with 15N and/or 13C was achieved by growing the bacteria in minimal medium supplemented with 15(NH4)2SO4 and/or 13C6-glucose as the sole nitrogen and carbon sources. His6-CaCdc42 was purified from bacterial lysate by absorption onto a Ni—NTA column (Qiagen) under native conditions (20 mM Tris-HCl, 500 mM NaCl and 2 mM MgCl2 at pH 8.0, 15 mM immidazole) and eluted with a 30 mM to 300 mM immidazole gradient. Following buffer exchange into 20 mM Tris-HCl, 2 mM MgCl2 at pH 8.0, the His6-tag was removed with thrombin and the thrombin inhibitor PPACK added to halt the cleavage reaction. CaCdc42 was obtained after application to a Q-Sepharose™ column and eluted with a 0 to 400 mM NaCl gradient. An activated form of Cdc42 was generated using the non-hydrolysable GTP analogue, β,γ-methyleneguanosine 5′-triphosphate, or GMPPCP (SIGMA). Due to the similar affinity of GDP and GMPPCP for Cdc42, alkaline phosphatase beads were used to degrade GDP as follows. The GDP-loaded form of CaCdc42 was exchanged into a buffer that was 20 mM in Tris, 2 mM MgCl2, at pH 8.0. Ammonium sulfate was added to a final concentration of 0.2 M. Excess Mg2+ was removed by adding 20 mM EDTA. GMPPCP was then added to a 10-fold molar excess of Cdc42 and the mixture added to alkaline phosphatase beads (˜100 units) and shaken gently for 2 hours. The beads were then removed by low speed centrifugation and 25 mM MgCl2 were added. NMR samples were obtained after exchange into a buffer containing 50 mM phosphate, 2 mM MgCl2, 50 mM NaCl, pH 6.15 using a PD-10 column.
Peptide Preparation
The peptide N-acetyl-*D55F*E*E*IP60EEYLQ65 (N-acetyl-Hir(55-65)) was enriched selectively with 15N isotopes at the amides of five residues Asp55, Phe56, Glu57, Glu58 and Ile59 as described previously (Carpenter, K. A. and Ni, F. (1992) J.Magn.Reson. 99, 192-197). Dried powder of the purified peptide was weighed using a Sartorius Supermicro S4™ balance and dissolved at ˜1.5 mM in an aqueous solution (10% D2O) that was 50 mM in NaCl and 50 mM in sodium phosphate at pH 5.5. Carefully measured volume aliquots of human prothrombin at a stock concentration of 0.3 mM were added to the peptide solution to produce molar ratios of ˜1:45, ˜1:35, and ˜1:30 for the prothrombin and peptide concentrations, respectively.
A small fusion sequence, termed SFC120, was used as the carrier protein to express all the 15N-labeled peptides used in this application. SFC120 was adopted for peptide production from the N-terminal oligonucleotide binding domain of M. ribonuclease HL which comprises 120 amino acid residues. The cDNA was amplified by standard PCR methods while the restriction enzyme site of Nco I was generated in the 5′-end and the two restriction enzyme sites of EcoR I and BamH I were generated in the 3′-end. The PCR product was double-digested by Nco I and BamH I and ligated into the pET15M vector, which was modified from the pET-15b vector (Novagen) by removing the EcoR I site. The constructed fusion protein expression vector was termed as pTSN-6A.
The DNA fragments encoding the peptides were amplified from a cDNA library by PCR or synthesized as oligonucleotides using the codon preference of E coli. The DNA fragments were digested with EcoR I and BamH I, and subcloned into the pTSN-6A vector. The expression constructs were transformed into the BL21(DE3) expression host and confirmed by DNA sequencing. A single methionine residue was inserted between the fusion protein and the desired peptide sequence to facilitate release of the peptides by CNBr cleavage. A His-tag with six histidines can be placed at the N-terminus of SFC120 to allow purification of the fusion protein by adsorption onto a Ni—NTA agarose column (QIAGEN). In the present case, the His-tagged SFC120 vector was used to express the peptide FD22 (see Examples 4 and 7). Non-His-tagged SFC120 was used to express the rest of the peptides.
Expression of the peptide fragments was achieved by transformation of the appropriate plasmid into E. coli BL21(DE3) competent cells. An overnight culture grown in 2YT containing 100 μg/ml ampicillin (25 ml) was used to inoculate 1 L of M9 minimal media (100 μg/ml ampicillin) supplemented with BME vitamins solution (10 ml/L of 100× stock—SIGMA). 15N-labeled peptides were expressed using 15(NH4)2SO4 (2 g/L) as the sole nitrogen source. The cells were grown at 37° C. to a cell density of OD600=0.8 and induced by adding IPTG to a final concentration of 1 mM. The cells were incubated for 4-12 hours at 37° C. and collected by centrifugation (8000 g for 20 minutes).
Cell pellets were resuspended in 6 M urea in 20 mM Tris, 100 mM NaCl buffer, pH 8.0 for 4 hours and then sonicated for 45 seconds on ice. The solution was then centrifuged at 7 K rpm for 20 minutes. An equivolume of 100% cold ethanol was added to the supernatant and the solution allowed to stand at 4° C. for two hours. After centrifugation, another equivolume of cold ethanol was added to the supernatant and allowed to stand overnight. The solution was centrifuged at 8,500 rpm and the pellet containing the pure fusion-peptide fragment subjected to SDS-page analysis. If necessary the pellet was further resuspended in 6 M urea and applied to a Sep-Pak™ column (Waters) to remove any impurities. The fusion protein was then lyophilized.
An additional step of purification on a Ni—NTA agarose column for His-tagged fusion peptides was performed as follows. Cell pellets were resuspended in 6 M urea in Tris-HCL buffer at pH 8.0 by gentle shaking for ˜4 hours and briefly sonicated on ice. After centrifugation at 7 K rpm for 20 minutes the supernatant was applied to a Ni—NTA agarose column (QIAGEN) previously equilibrated with the lysis buffer. The column was then washed with ˜20 column volumes of 6 M urea in Tris buffer at pH 6.3 to eliminate non-specific binding to the column. The His-tagged fusion protein was then eluted with 6 M urea in 20 mM Tris buffer at pH 4.5. The solubilized fusion protein was then lyophilized to dryness.
CNBr cleavage was used to release the target peptide from the fusion protein as follows. The fusion protein was dissolved in 70% TFA, CNBr added to a final molar ratio of 100:1 and the solution allowed to stand for ˜24 hours. The samples were then diluted with water (×10) and lyophilized to dryness and purified by RP-HPLC on a C18 column using an acetonitrile-water gradient containing 0.1% TFA. The peptides were lyophilized and there identity was confirmed by electrospray mass spectrometry. Free peptides were prepared for NMR analysis by resuspending the lyophilized peptides into the appropriate NMR buffer solution.
The mixture of the fragments F1, F2, F3, F4, and F5 of human cathepsin B were prepared as follows. The fusion protein was purified by GST affinity chromatography followed by the proteolytic removal of the carrier protein using thrombin as the cleavage enzyme. The intact mutant propeptide was further purified by HPLC and cleaved by CNBr in the solution of 50% formic acid for 24 hours at room temperature. The peptide mixture was desalted either by dialysis or by a Sep-Pak™ reversed-phase C18 column. The peptide mixture was then lyophilized and dissolved in 50 mM sodium acetate-d3 buffer, pH 5.5-6.0.
Titration of the thrombin-cleaved FD22 peptide was carried out as follows. The sample of FD22 was concentrated by Speed-Vac to 40 μl and 180 μl of a concentrated thrombin solution were added to give a final thrombin:peptide ratio of approximately 1:20 in 60 mM sodium phosphate buffer, 0.2 mM EDTA, 10% D2O, at pH 5.5. Additional steps of thrombin titrations were carried out by the addition of the human □-thrombin concentrated to ˜8 mg/ml.
NMR Signal Assignments of the 15N-Labeled Peptides
Proton resonance assignment for the N-acetyl-Hir(55-65) peptide was achieved by using 2D NOESY-[1H,15N]—HSQC with an NOE mixing time of 250 ms and 2D TOCSY-[1H,15N]—HSQC with a TOCSY mixing time of 56.6 ms (Cavanagh, J., Fairbrother, W. J., Palmer, A. G., and Skelton, N. J. (1995) Protein NMR Spectroscopy: Principles and Practice. Academic Press, San Diego) spectra recorded at 288 K and 500 MHz. Amino acid residues were identified on the basis of the cross-peak patterns from the TOCSY spectrum, and assigned through sequential NOE connectivities. 15N resonances were assigned using a [1H—15N] HSQC (Cavanagh, J., Fairbrother, W. J., Palmer, A. G., and Skelton, N. J. (1995) Protein NMR Spectroscopy: Principles and Practice. Academic Press, San Diego) spectrum acquired at 288 K and 500 MHz.
Proton resonance assignment for the recombinantly expressed 15N-labeled Hir(54-65) peptide was achieved by using 2D NOESY-[1H,15N]—HSQC with an NOE mixing time of 250 ms and 2D TOCSY-[1H,15N]—HSQC with a TOCSY mixing time of 60.48 ms spectra recorded at 288 K and 800 MHz. Amino acid residues were identified on the basis of the cross-peak patterns from the TOCSY spectrum, and assigned through sequential NOE connectivities. 15N resonances were assigned by using a 2D [1H,15N]—HSQC-TOCSY spectrum with a TOCSY mixing time of 55.76 ms (Cavanagh, J., Fairbrother, W. J., Palmer, A. G., and Skelton, N. J. (1995) Protein NMR Spectroscopy: Principles and Practice. Academic Press, San Diego) acquired at 288 K and 800 MHz.
Resonances of the thrombin-cleaved 15N-labeled FD22 peptide were assigned by use of two homonuclear experiments, NOESY with an NOE mixing time of 250 ms and TOCSY with a TOCSY mixing time of 58.32 ms, were recorded at 288 K and 500 MHz. In both experiments, 15N decoupling was applied during the t1 and t2 periods, and the water resonance was flipped-back to the +Z axis prior to data acquisition (Lippens, G., Dhalluin, C., and Wieruszeski, J.-M. (1995) J.Biomol.NMR 5, 327-331; and Fulton, D. B., Hrabal, R., and Ni, F. (1996) J.Biomol.NMR 8, 213-218; and Fulton, D. B. and Ni, F. (1997) J.Magn Reson. 129, 93-97). Amino acid residues were identified on the basis of the cross-peak patterns from the TOCSY spectrum, and assigned through sequential NOE connectivities. 15N resonances were assigned by using 2D [1H,15N]—HSQC-TOCSY with a TOCSY mixing time of 55.44 ms acquired at 288 K and 800 MHz.
Assignments for the 15N labeled CRIB peptides were obtained in a sequential manner from homonuclear 1H—1H 2D and 3D 15N-edited TOCSY and NOESY spectra.
Measurements of the 15N NMR Relaxation Dispersion Profiles
The sample temperatures were calibrated using methanol (Cavanagh, J., Fairbrother, W. J., Palmer, A. G., and Skelton, N. J. (1995) Protein NMR Spectroscopy: Principles and Practice. Academic Press, San Diego). The core of the NMR relaxation dispersion measurements is the relaxation-compensated CPMG pulse scheme (
Fitting of the NMR Relaxation Dispersion Profiles and Derivation of the Dissociation Rate Constants koff
Under the experimental conditions, the NMR magnetization M in the rotating frame was assumed to evolve between the 180° refocusing pulses according to the following equations:
for a two-state exchange model, and
for a three-state exchange model (Jen, J. (1978) J.Magn Reson. 30, 111-128).
The notation for the exchange rate constants is shown in
The two-state exchange model can be fit to the experimental relaxation dispersion curves by use of a single exponential approximation, which is valid for all exchange conditions when the concentration of the free ligand is in large excess over that of the bound states (Carver, J. P. and Richards, R. E. (1972) J.Magn.Reson. 6, 89-105; and Jen, J. (1978) J.Magn Reson. 30, 111-128; and Davis, D. G., Perlman, M. E., and London, R. E. (1994) J.Magn Reson.B 104, 266-275; and Ni, F. (1994) Progress in NMR spectroscopy 26, 517-606). In this case the following equations relate the NMR relaxation dispersion profiles to the underlying physical parameters (Carver, J. P. and Richards, R. E. (1972) J.Magn.Reson. 6, 89-105; and Jen, J. (1978) J.Magn Reson. 30, 111-128; and Davis, D. G., Perlman, M. E., and London, R. E. (1994) J.Magn Reson.B 104, 266-275),
R2eff−ln[I(1/τCPMG)/I(0)/T=(R2f+R2bkoffkon′)/2−(1/τCPMG)ln λ+ (2)
where
lnλ+½cosh−1[D+cos2ξ−D−cos2η]; (2a)
D±=½[±1+(ψ+2δωbf2)/(ψ2ξ2)1/2]; (2b)
ξ=(τCPMG/√8)[+ψ+(ψ2+ξ2)1/2]1/2; (2c)
η=(τCPMG/√8)[−ψ+(ψ2+ξ2)1/2]1/2; (2d)
ψ=(R2f−R2b+kon′−koff2−δωbf2+4kon+koff (2e)
ξ=δωbf(R2f−R2b+kon′−koff) (2f)
δωbf=δωb−δωf. (2g)
For three-site exchange situation, the magnetization evolution can be obtained by numeric integration of the equations (1) and fit to the experimental NMR relaxation data (Jen, J. (1978) J.Magn Reson. 30, 111-128; and Tollinger, M., Skrynnikov, N. R., Mulder, F. A., Forman-Kay, J. D., and Kay, L. E. (2001) J.Am;Chem.Soc. 123, 11341-11352). For the specific application herein, values for koff, kon′, koff1, koff2, kon−1, k1, k2, R2b(500 MHz), R2b(800 MHz), δωb, δωb1 and δωb2 (
Error Evaluation
The errors of fitting the kinetic and NMR relaxation parameters using Equations 1 and 1a to 1d were estimated through Monte-Carlo sampling as follows. Random deviations of the measured peak integral intensities were generated for each of the 200 Monte-Carlo samples. The absolute value of the deviation was set to 1% of the intensity corresponding to zero relaxation delay, which was a justifiable uncertainty based on a few independent experiments. Error analysis for curve fitting using Equations 2 and 2a to 2g was carried out in a slightly different manner. The standard deviations of the fitted parameters were estimated through (bootstrap) Monte Carlo simulations (Press, W. H., Teukolsky, S. A., Vetterling, W. T., and Flannery, B. P. (1992) Numerical Recipes in Fortran. Cambridge University Press) using a maximum deviation of ±10% for all experimental R2 values.
Quantitative Analysis of Ligand NMR Relaxation Dispersion Profiles of Transient Protein-Ligand Complexes
15N NMR Relaxation Dispersion Profiles of an Anti-Thrombin Peptide Interacting With Human Prothrombin.
The anti-thrombin peptide N-acetyl-*Asp-*Phe-*Glu-*Glu-*Ile-Pro-Glu-Glu-Tyr-Leu-Gln (SEQ ID NO:15)(to be referred to as N-acetyl-Hir(55-65) in the subsequent descriptions), contains five 15N-labeled residues Asp55, Phe56, Glu57, Glu58 and Ile59 at their backbone amide nitrogens. The peptide free in solution displays slowly relaxing (sharp) NMR signals with no detectable response (
Data Analysis Using a Two-Site Exchange Model
A two-site exchange model was fitted independently for every 1H/15N cross-peak either at each prothrombin concentration or by combining the data for all three prothrombin concentrations. In this scheme, pb is the bound population of the peptide, δωbf is the 15N resonance peak separation (δωb−δδωf) between the bound and the free states, R2f is the transverse relaxation rate for the free peptide, R2b is the transverse relaxation rate for the bound peptide, koff is the dissociation rate constant, kon′=kon×[Ef] is a pseudo-first order binding rate constant, where kon is the association rate constant, and [Ef] is the concentration of the free prothrombin. In turn, the concentration of the free prothrombin [Ef] is defined by the concentration of the free peptide [Lfree], the total concentration of added prothrombin [E0], and an equilibrium dissociation constant KD (which in the case of a two-state exchange is equal to koff/kon) as
[Ef]=[E0]KD(KD+[Lfree]), (3)
which in the case of [Lfree]>>KD, and [L0]>>[E0], is proportional to the [E0]/[L0] ratio. A least squares fitting procedure was used to extract the values of R2b at the two magnetic fields, koff, pb, and δωbf. The values of R2f, the transverse relaxation rate for the 15N-labeled sites of the free peptide, were derived from the CPMG relaxation dispersion profile of the free peptide (
The results of the fits are presented in Table 1. It is seen that the behavior of residues Phe56 and Ile59 is consistent with a two-site exchange model. Both residues display highly similar koff and R2b values independent of the peptide/prothrombin ratio, and pb is growing roughly proportionally to the added prothrombin. Glu58, on the other hand, has a noticeably different behavior: the calculated koff value decreases with the addition of prothrombin, while R2b increases, and pb is not changing. Glu57 displays some growth of koff and only slight increase in pb upon the incremental growth of the prothrombin concentration. In addition, R2b values for Glu57 at both fields appear to be unusually high, almost doubling the values calculated for other 15N sites. Regardless, fitting results with residues Phe56 and Ile59 indicate that 15N-relaxation dispersion data at two magnetic fields and at a single prothrombin concentration can uniquely determine the five unknown parameters, R2b(500), R2b(800), koff, pb and δωbf describing two-state binding.
1The fitted parameters koff, δωbf, pb and R2b represent, respectively, the dissociation rate constant of the protein-peptide complex, the frequency separation for a peptide15N signal in the free and bound states (δωb-δωf), the apparent fraction of the bound peptide, and the apparent R2 relaxation rate
2Fitted values of δωbf were 3.1 ± 0.1, (−1.2) ± 1.8, and (−5.5) ± 0.1 ppm, for residues Phe56, Glu57 and Ile59, respectively.
A simultaneous fit of the dispersion curves was then carried out at all three prothrombin concentrations, using the fact, that kon′ is proportional to [Ef], hence to [E0] (Equation 3). Three matrices REX(1:45), REX(1:35), and REX(1:30) for each prothrombin:peptide ratio were used to fit simultaneously relaxation dispersion curves from three prothrombin concentrations. Matrices REX(1:35) and REX(1:30) are produced from, REX(1:45) by substituting exchange rates kon′ (or kon−1 and kon−2 in the models with two dissociation routes) with 1.29×kon′ (or 1.29×kon−1 and 1.29×kon−2) and 1.5×kon′ (or 1.5×kon′ (or 1.5×kon−1 and 1.5×kon−2), respectively. The ratios 1.29 and 1.5 for REX(1:35) and REX(1:30) reflect the increase of prothrombin/ligand ratio in the relationship kon′˜KD[E0]/[L0] under the assumptions of [Lfree]>>KD and [L0]>>[E0] (see equations (3) and (4)), and are obtained using the volumes of the added prothrombin solution in the titration. The populations of different species with increased prothrombin concentrations were recalculated in accordance with the modified kon′ (or kon−1 and kon−2) values. The fit was performed independently for each 1H/15N cross-peak (
Simultaneous fitting of eighteen dispersion curves at the three concentrations of prothrombin for all three residues Phe56, Glu57 and Ile59 was also performed and is listed in the last row of Table 1. For this particular fitting, equal R2b values were assumed for each residue in the bound state to simplify the calculations. Whereas parameters for Phe56 and Ile59 remained similar to those obtained independently for every residue, the fit forced poor convergence of the parameter δωbf (1.2±1.8 ppm) for Glu57.
It was not possible to obtain a reasonable fit for residue Glu58 using a two-site exchange model at the three prothrombin concentrations (
Data Analysis Using a Three-Site Exchange Model
The relaxation behaviors of residues Glu57 and particularly Glu58 suggest the presence of other conformations for these residues in the bound state. Although the relaxation dispersion of Glu57 is possible to be fitted by a two-site exchange model at all three prothrombin concentrations, the abnormally high values of R2b as well as comparatively low values of pb, might be artifacts originating from the presence of additional exchange pathways. In fact, even residues Phe56 and Ile59 display R2b values somewhat higher than expected, if It is assumed that in the bound state it is the motions of the complex as a whole that define the transverse relaxation of the ligand. Theoretical values of R2 for a protein with the molecular mass of prothrombin (72 kDa) and order parameter S=0.8 and 1.0 were estimated to be respectively 95/122 and 119/153 s−1 at 500/800 MHz (Luginbuhl, P. and Wuthrich, K. (2002) Progress in NMR spectroscopy 40, 199-247).
In the most general case including additional bound state adds two kinetic pathways to the model (
In practice, it was found that the three-state system may be somewhat underdefined, and depending on the starting conditions, the calculation converged to a few clusters of fitted parameters. The clusters were filtered on the basis of physical feasibility, and parameter sets containing negative rate constants or relaxation times, as well as pb=pb1+pb2 exceeding or comparable with pfree=(1−pb), were not considered. To fit the experimental dispersion curves of Glu57 to a “linear” three-site model (
To “link” the process of binding-dissociation between different 15N sites of the peptide, fitting of all eighteen dispersion curves was performed for the three residues Phe56, Glu57 and Ile59 at three concentrations of prothrombin and at two magnetic fields (
The “forked” three-site mechanism (
In a general three-site exchange mechanism, the presence of two dissociation pathways as well as an exchange between two complex conformers is presumed (
In
Interestingly, both the “linear” and “full” three-state models failed to describe the relaxation behavior of the backbone 15N nucleus of Glu58. Although they produce a somewhat closer fit than two-site model, reducing X2 from ˜4.8 s−2 for two-site to ˜1.2 s−2 for three-site exchange, the calculated parameters are not physically reasonable.
The present invention will be more readily understood by referring to the following examples, which are given to illustrate the invention rather than to limit its scope.
The changes in 15N transverse relaxation dispersion of a selectively 15N-labeled N-acetyl-*Asp55-*Phe-*Glu-*Glu-*Ile-Pro60-Glu-Glu-Tyr-Leu-Gln65-COOH (SEQ ID NO:15)(N-acetyl-Hir(55-65)) were followed as a function of the concentration of the binding protein, human prothrombin. The 15N NMR transverse relaxation rate of the 11-residue peptide is not responsive to the CPMG pulse rate (
In the course of the titration with human prothrombin, each 15N labeled residue displayed slightly different relaxation behavior in response to increased prothrombin concentrations. Transverse relaxation of residue Asp55 showed a very weak response to the complex formation, implying a small change in chemical shift upon binding. This is in agreement with the very little binding-induced line broadening of the amide proton resonance of Asp55 reported previously (Ni, F., Ning, Q., Jackson, C. M., and Fenton, J. W. (1993) J.Biol.Chem. 268, 16899-16902). Contrary to Asp55, there is a pronounced increase in the transverse relaxation of residues 56-59 induced by binding with prothrombin. Residues Phe56 and Ile59 followed a two-site exchange model fairly well and displayed the same concentration-independent koff and R2b values at both magnetic fields (Table 1). In addition, the calculated bound population for these two residues rose proportionally to the amount of prothrombin added, and were roughly comparable with the absolute concentration of prothrombin. The value of the calculated koff rate was also quite reasonable. One can estimate the KD for the interaction of Hir(55-65) and N-acetyl-Hir(55-65) peptides with human prothrombin to be approximately 100-300 μM (Krstenansky, J. L., Owen, T. J., Yates, M. T., and Mao, S. J. (1987) J.Med.Chem. 30, 1688-1691; and Ni, F., Ning, Q., Jackson, C. M., and Fenton, J. W. (1993) J.Biol.Chem. 268, 16899-16902; and Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000) J.Biol.Chem. 275, 16428-16434). If one assumes the kon for N-acetyl-Hir(55-65) to be in the range of 107-108 M−1s−1, as reported for hirudin-based peptides (Skordalakes, E., Elgendy, S., Goodwin, C. A., Green, D., Scully, M. F., Kakkar, V. V., Freyssinet, J. M., Dodson, G., and Deadman, J. J. (1998) Biochemistry 37, 14420-14427; and Myles, T., Le Bonniec, B. F., Betz, A., and Stone, S. R. (2001) Biochemistry 40, 4972-4979; and Betz, A., Hofsteenge, J., and Stone, S. R. (1991) Biochem.J. 275 (Pt 3), 801-803), koff=KDkon can be estimated as 103-104 s−1, in good agreement with the koff value determined here by use of 15N NMR relaxation dispersion spectroscopy (Table 1).
Residues Glu57 and Glu58 displayed a complex NMR relaxation behavior suggesting the presence of other binding states. The most obvious deviation from a simple two-state binding was found for Glu58. The transverse relaxation of Glu58 was growing with the addition of prothrombin too slowly to be consistent with either two-state or even three-state exchange models, although the three-state model represented a slightly better description. Although the relaxation dispersion curves of Glu57 were possible to be fitted to a two-state exchange model, the apparent values of R2b for Glu57 were significantly higher, whereas pb was lower than those of Phe56 and Ile59. To establish if extension of the exchange model to a three-state process will produce more realistic values of R2b and pb, the relaxation of the peptide was analyzed at all three prothrombin concentrations simultaneously. Since the rate constants of the conformational exchange between the bound states do not depend on the prothrombin concentration, whereas the pseudo-first order binding rate constant is proportional to [Ef], titration by the binding protein may in principle help isolate the contributions of ligand association-dissociation and conformational change of the protein-ligand complex to the observed transverse relaxation. The fitted k1 and k2 rates for the conformational change were on the order of 100 s−1 for the prothrombin-peptide complex which is comparable with those (˜115 and ˜185 s−1, respectively) obtained with the stopped-flow fluorescence spectroscopy for thrombin-peptide interactions (Jackman, M. P., Parry, M. A., Hofsteenge, J., and Stone, S. R. (1992) J.Biol.Chem. 267, 15375-15383). At the same time, R2b and pb values turned out to be closer to the expected physically meaningful values, than those obtained by a two-state exchange scheme. It appears that the koff value obtained from the “linear” three-site exchange scheme might be underestimated by a two-site model, but not dramatically.
The contributions of multi-site exchanges or conformational changes of the protein-ligand complex can be assessed by a full three-state exchange scheme (
In summary, the dissociation rate koff can be obtained by fitting a two-state exchange model to the 15N relaxation dispersion curves obtained for the N-acetyl-Hir(55-65) peptide at two external magnetic fields and at three prothrombin concentrations (
The different binding behavior of ligand sites can be further verified by the temperature dependence of the dissociation rate constants of a protein-ligand complex. The peptide 15N relaxation dispersion was collected at three different temperatures for the N-acetyl-Hir(55-65) peptide in complex with human prothrombin (Table 2 and
In
A peptide Gly54-Asp55-Phe56Glu57-Glu58-Ile59-Pro60-Glu61-Glu62-Tyr63-Leu64-Gln65 (SEQ ID NO:19)(Hir(54-65)), related to the N-acetyl-Hir(55-65) peptide, was recombinantly expressed and uniformly labeled with the 15N isotope. The Hir(54-65) peptide was dissolved at ˜1.5 mM in an aqueous solution that was 50 mM in sodium phosphate at pH 5.5. NMR peak assignments were carried out as described hereinabove. The free peptide produces relaxation dispersion curves independent of the CPMG pulse rate (
In
In
The peptide N-acetyl-Hir(55-65) also binds to human thrombin with a higher affinity than for the same site on human prothrombin (Ni, F., Ning, Q., Jackson, C. M., and Fenton, J. W. (1993) J.Biol.Chem. 268, 16899-16902).
1Rows denoted with asterisk show the results of the fitting with a single-exponential approximation.
In
A special procedure was used to express six uniformly 15N-labeled hexa/penta-peptides, GLDPRHL (SEQ ID NO:1), GVDPRHL (SEQ ID NO:2), GFNPRHL (SEQ ID NO:3), GPNPRHL (SEQ ID NO:4), GFSARHL (SEQ ID NO:5), and GVSPR (SEQ ID NO:6), where a one-letter code is used to define the amino acid sequence, and HL stands for homoserine lactone. The six short peptides were expressed in tandem as a linear sequence GLDPRMGVDPRMGFNPRMGPNPRMGFSARMGVSPR (SEQ ID NO:16). The individual peptides were released by CNBr cleavage at the methionine residues, producing the homoserine lactone (HL) derivatives of the pentapeptides. Upon introduction of the hexa/pentapeptides in the sample of the N-acetyl-Hir(55-65)-thrombin complex (see Example 3), the five 1H—15N HSQC cross-peaks of the N-acetyl-Hir(55-65) peptide were still easily resolved and identifiable (
Quantitative koff determination was carried out for the mixture of a short peptide Phe-Asp45-Pro-Arg (FD22-N)(SEQ ID NO:17) with Pro-Gln-Ser50-His-Asn-Asp-Gly-Asp55-Phe-Glu-Glu-Ile-Pro60-Glu-Glu-Tyr-Leu-Gln65 (FD22-C) (SEQ ID NO:18), which contain the sequence of the N-acetyl-Hir(55-65) peptide. Calculated apparent koff values for the peptides FD22-N and FD22-C are presented in Table 5. Experimental values for every residue (
In
1Every residue, except for Phe56 and Arg47, lists parameters obtained by a simultaneous fit to dispersion data at three α-thrombin concentrations using kon′, 1.52 × kon′, and 2.78 × kon′ for the pseudo-first-order association rate constants. Values in pb column for these residues correspond to
The NMR relaxation dispersion technique can also be used to detect co-operative binding between two peptide ligands as shown in
These experiments illustrated in
In
Recombinant expression was used to prepare a mixture of four hirudin-based and uniformly 15N-labeled peptides, Hir(54-65) (GDFEEIPEEYLQ) (SEQ ID NO:19), HRC2 (GDYEEIPEEYLQHL) (SEQ ID NO:12), HRC3 (GDLEEIPEEYLQHL) (SEQ ID NO:13), and HRC4 (GDGEEIPEEYLQ) (SEQ ID NO:14), where a one-letter code is used to define the amino acid sequence, and HL stands for homoserine lactone. The peptide sequences differ in the third amino acid position and the presence of the homoserine lactone at the C-terminus. The 15N relaxation dispersion profiles were collected for the peptide mixture in the presence of sub-equimolar amounts of human prothrombin (
15N relaxation dispersion curves were collected for the two 15N labeled CRIB peptides, mSte20 and mCla4 (
A peptide named FD22, has been discovered as a potent bivalent inhibitor of human thrombin with IC50≈20 nM. FD22 has the sequence of Phe-Asp45-Pro-Arg-Pro-Gln-Ser50-His-Asn-Asp-Gly-Asp55-Phe-Glu-Glu-Ile-Pro60-Glu-Glu-Tyr-Leu-Gln65 (SEQ ID NO:20) and binds to thrombin via both the anion-binding exosite-I and the catalytic active site. The addition of active thrombin to the peptide FD22 (dissolved at a concentration of ˜0.9 mM in 50 mM sodium phosphate buffer, 10% D2O, 0.2 mM EDTA, at pH 5.5), caused slow and specific proteolytic cleavage at the Arg47-Pro48 peptide bond (taking >60 hours for the cleavage to complete). Upon completion of the cleavage, the sample contains a mixture of two peptides, Phe-Asp45-Pro-Arg (FD22-N) (SEQ ID NO:17) and Pro-Gln-Ser50-His-Asn-Asp-Gly-Asp55-Phe-Glu-Glu-Ile-Pro60-Glu-Glu-Tyr-Leu-Gln65 (FD22-C) (SEQ ID NO:18) that should bind separately to the active site and the anion-binding exosite I of thrombin. Residues Phe56, Glu57, Glu58, Ile59, Tyr63, Leu64 and Gln65 of the 55-65 region of the FD22-C fragment displayed pronounced resonance line broadening and 15N NMR relaxation dispersion (
The results obtained with the FD22 peptide indicate that the present techniques can also provide binding information for tight and essentially irreversible protein-protein complexes. This is exquisitely illustrated for the complexes of the Cdc42 protein with peptide fragments derived from two signaling kinases (
For these experiments, two peptide fragments of the extended CRIB region from the Cla4 kinase (
15N relaxation dispersion spectroscopy was then used to probe the kinetics (specifically the off-rates), of the transient mCRIB complexes with Cdc42 in order to rank the relative affinities of similar peptide fragments.
In
A large and tight-binding protein or peptide can also be fragmented into more than two subfragments for use in NMR relaxation dispersion studies. This is illustrated with the propeptide of human cathepsin B (
In
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/CA03/00014 | 1/10/2003 | WO | 6/17/2005 |
Number | Date | Country | |
---|---|---|---|
60346894 | Jan 2002 | US |